Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS1007 PK/PD study in granulomatosis with polyangiitis
2018-003903-21Phase 2Terminated
- Sponsor
- Insmed Incorporated
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of brensocatib in granulomatosis with polyangiitis (GPA) (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Change from baseline in exploratory pharmacodynamic biomarkers. Started Feb 2019; status: terminated.
02
Drugs
brensocatib
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on 2018-003903-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003903-21.